T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.
CITATION STYLE
Gottschalk, S., Bollard, C. M., Straathof, K. C., Louis, C. U., Savoldo, B., Dotti, G., … Rooney, C. M. (2006). T cell therapies. Ernst Schering Foundation Symposium Proceedings. https://doi.org/10.1093/med/9780198831433.003.0033
Mendeley helps you to discover research relevant for your work.